Inflammatory Consequences of Crystalloids in Severely Burned Patients (NCT04893382) | Clinical Trial Compass
TerminatedNot Applicable
Inflammatory Consequences of Crystalloids in Severely Burned Patients
Stopped: Lack of funds and participants
Canada14 participantsStarted 2021-10-17
Plain-language summary
This is a pilot study, but the investigators will also observe key immunological events with potential significance. The global objective is to study the inflammatory profiles of PlasmaLyte and Ringer's Lactate used in the initial massive fluid resuscitation of severely burned patients. On the long term, the investigators will identify the crystalloid that prevents hyperactivation of macrophages and death of severely burned patients.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* admission to the CHUM
* more than 20% of burned area
* first blood withdrawal in the first 24 hours following burn
Exclusion Criteria:
* immunosuppression
* chemotherapy 6 months before admission
* radiotherapy 6 months before admission
* autoimmune diseases
* neoplasia
* pregnancy
* severe infections
* cardiac dysfunctions
* renal dysfunction
* hepatic dysfunctions
* Hepatitis C
* HIV
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in monocyte phenotype from admission to day 10
Timeframe: Pre-infusion to day 10 post-infusion
Trial details
NCT IDNCT04893382
SponsorCentre hospitalier de l'Université de Montréal (CHUM)